Biomedical Engineering Reference
In-Depth Information
54. Jarraya B, Boulet S, Ralph GS et al (2009)
Dopamine gene therapy for Parkinson's dis-
ease in a nonhuman primate without associ-
ated dyskinesia. Sci Transl Med 1:2ra4
55. Muramatsu S, Fujimoto K, Kato S et al (2010)
A phase I study of aromatic L-amino acid
decarboxylase gene therapy for Parkinson's
disease. Mol Ther 18:1731-1735
56. Christine CW, Starr PA, Larson PS et al (2009)
Safety and tolerability of putaminal AADC
gene therapy for Parkinson disease. Neurology
73:1662-1669
57. Eberling JL, Jagust WJ, Christine CW et al
(2008) Results from a phase I safety trial of
hAADC gene therapy for Parkinson disease.
Neurology 70:1980-1983
58. Nathwani AC, Tuddenham EG, Rangarajan S
et al (2011) Adenovirus-associated virus
vector-mediated gene transfer in hemophilia
B. N Engl J Med 365:2357-2365
59. Kay MA, Manno CS, Ragni MV et al (2000)
Evidence for gene transfer and expression of
factor IX in haemophilia B patients treated
with an AAV vector. Nat Genet 24:257-261
60. High KA (2001) AAV-mediated gene transfer
for hemophilia. Ann N Y Acad Sci 953:64-74
61. Pollack A (2012) European agency backs
approval of a gene therapy. New York Times,
New York edition 21 Jul, Sect. B (Health), p. B1
62. Mingozzi F, High KA (2013) Immune
responses to AAV vectors: overcoming barriers
to successful gene therapy. Blood 122:23-36
63. Semenza GL, Wang GL (1992) A nuclear fac-
tor induced by hypoxia via de novo protein
synthesis binds to the human erythropoietin
gene enhancer at a site required for transcrip-
tional activation. Mol Cell Biol 12:5447-5454
64. Wang GL, Semenza GL (1993) General
involvement of hypoxia-inducible factor 1 in
transcriptional response to hypoxia. Proc Natl
Acad Sci U S A 90:4304-4308
65. Ruan H, Su H, Hu L et al (2001) A hypoxia-
regulated adeno-associated virus vector for can-
cer-specifi c gene therapy. Neoplasia 3:255-263
66. Pachori AS, Melo LG, Hart ML et al (2004)
Hypoxia-regulated therapeutic gene as a pre-
emptive treatment strategy against ischemia/
reperfusion tissue injury. Proc Natl Acad Sci
U S A 101:12282-12287
67. Shibata T, Giaccia AJ, Brown JM (2000)
Development of a hypoxia-responsive vector
for tumor-specifi c gene therapy. Gene Ther
7:493-498
68. Gao GP, Alvira MR, Wang L et al (2002)
Novel adeno-associated viruses from rhesus
monkeys as vectors for human gene therapy.
Proc Natl Acad Sci U S A 99:11854-11859
69. Rutledge EA, Halbert CL, Russell DW (1998)
Infectious clones and vectors derived from
adeno-associated virus (AAV) serotypes other
than AAV type 2. J Virol 72:309-319
70. Muramatsu S, Mizukami H, Young NS et al
(1996) Nucleotide sequencing and generation
of an infectious clone of adeno-associated virus
3. Virology 221:208-217
71. Chiorini JA, Yang L, Liu Y et al (1997)
Cloning of adeno-associated virus type 4
(AAV4) and generation of recombinant AAV4
particles. J Virol 71:6823-6833
72. Chiorini JA, Kim F, Yang L et al (1999)
Cloning and characterization of adeno-
associated virus type 5. J Virol 73:1309-1319
73. Xiao W, Chirmule N, Berta SC et al (1999)
Gene therapy vectors based on adeno-
associated virus type 1. J Virol 73:3994-4003
74. Zhang L, Schallert T, Zhang ZG et al (2002)
A test for detecting long-term sensorimotor
dysfunction in the mouse after focal cerebral
ischemia. J Neurosci Methods 117:207-214
75. Bouet V, Freret T, Toutain J et al (2007)
Sensorimotor and cognitive defi cits after tran-
sient middle cerebral artery occlusion in the
mouse. Exp Neurol 203:555-567
76. Pang L, Ye W, Che XM et al (2001) Reduction
of infl ammatory response in the mouse brain
with adenoviral-mediated transforming
growth factor-ss1 expression. Stroke 32:
544-552
Search WWH ::
Custom Search